Bladder is a hollow organ in the lower part of the abdomen, that stores urine before passing it out of the body. The most common type of bladder cancer is transitional cell carcinoma that begins in the urothelial cells lining the bladder. The other two types of bladder cancer include squamous cell carcinoma and adenocarcinoma. Some of the symptoms associated with bladder cancer include blood in the urine, frequent urination, pain during urination, urinary incontinence, and pain in the lower part of the tummy or back. Though, the exact cause of bladder cancer is unknown, the disease usually occurs when cells in the bladder start growing abnormally and invade other tissues.
Current drug therapies for bladder cancer include chemotherapy and immunotherapy. The drug candidates for bladder cancer treatment include, but are not limited to, TLD1433, CVA21, and HS-410. Top pharmaceutical companies such as AstraZeneca plc, Eli Lilly and Company, and F. Hoffmann-La Roche AG are expected to launch their products in the coming years for the treatment of bladder cancer.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.